Stockscreener 앱 받기
8.485
13.51%
-1.325
Kyverna Therapeutics Inc 주식(KYTX)의 최신 뉴스
Cartesian Therapeutics Inc. : RNAC - 24/7 Wall St.
Kyverna Therapeutics (NASDAQ:KYTX) Shares Down 11.1%Time to Sell? - MarketBeat
Enterprise value to EBIT forward of Kyverna Therapeutics, Inc. – NASDAQ:KYTX - TradingView
Price to sales forward of Kyverna Therapeutics, Inc. – NASDAQ:KYTX - TradingView
Price to book forward of Kyverna Therapeutics, Inc. – NASDAQ:KYTX - TradingView
Kyverna Therapeutics (KYTX) Jefferies London Healthcare Conference 2025 Summary - Quartr
Kyverna Therapeutics’ (KYTX) Insights into Stiff Person Syndrome and Beyond - Insider Monkey
Kyverna Therapeutics, Inc. Files 8-K: Key Details on Nasdaq Listing, Emerging Growth Status, and Executive Signatures - Minichart
Kyverna Therapeutics Amends Term Loan, Extends Capital Access - TipRanks
Kyverna Therapeutics (KYTX) extends access to $150M term loan tranches - Stock Titan
Kyverna Therapeutics, Inc. $KYTX Shares Bought by AIGH Capital Management LLC - MarketBeat
Nine biopharma companies name legal officers - BioXconomy
Kyverna Therapeutics: The Autoimmune CAR T Beachhead Is Bigger Than SPS (KYTX) - Seeking Alpha
KYTX Stock Soars After Hours: What’s Driving The Rally? - Stocktwits
KYTXKyverna Therapeutics Inc Dividends - Finviz
Kyverna Therapeutics, Inc.(NasdaqGS: KYTX) added to Russell 2000 Index - marketscreener.com
Kyverna Therapeutics, Inc.(NasdaqGS: KYTX) added to Russell 2500 Growth Benchmark - marketscreener.com
Kyverna Therapeutics, Inc.(NasdaqGS: KYTX) added to Russell 2000 Value Benchmark - marketscreener.com
Kyverna Therapeutics, Inc.(NasdaqGS:KYTX) added to Russell Microcap Growth Benchmark Index - marketscreener.com
Kyverna Therapeutics, Inc.(NasdaqGS: KYTX) added to Russell 2000 Growth Benchmark - marketscreener.com
Kyverna Therapeutics, Inc.(NasdaqGS: KYTX) added to Russell 3000E Growth Benchmark - marketscreener.com
Kyverna Therapeutics, Inc.(NasdaqGS: KYTX) added to Russell 3000E Index - marketscreener.com
Kyverna Therapeutics, Inc.(NasdaqGS: KYTX) added to Russell 3000E Value Benchmark - marketscreener.com
Cabaletta Bio: The Market Sold The EULAR News, I'm Buying (NASDAQ:CABA) - Seeking Alpha
Kyverna Therapeutics, Inc. Actuals & Estimates (NASDAQ:KYTX) - TradingView
KYTX Forecast — Price Target — Prediction for 2027 - TradingView
Kyverna Therapeutics Appoints Ritesh Srivastava as Chief Legal and Compliance Officer, Adding Leadership Strength to Support Commercial-Stage Transition - The Manila Times
Kyverna Therapeutics Appoints Ritesh Srivastava as Chief - GlobeNewswire
Press Release: Kyverna Therapeutics Names Greg Martini as Chief Financial Officer - Moomoo
KYTX News | KYVERNA THERAPEUTICS INC (NASDAQ:KYTX) - ChartMill
KYVERNA THERAPEUTICS INC (KYTX) Stock Chart - ChartMill
Kyverna Therapeutics Inc (KYTX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Kyverna Therapeutics Inc (KYTX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Kyverna Therapeutics Inc (KYTX) Institutional Confidence - TradingKey
Kyverna Therapeutics Inc (KYTX) Valuation: PE, PB & Fair Value Analysis - TradingKey
Kyverna Therapeutics Inc (KYTX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Kyverna Therapeutics Inc (KYTX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
KYVERNA THERAPEUTICS INC (KYTX) Stock Price & Overview - ChartMill
Kyverna Therapeutics Inc (KYTX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Kyverna Therapeutics Inc (KYTX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Kyverna Therapeutics Inc (KYTX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Kyverna Therapeutics (KYTX) Posts Modest Gain Amid Biotech Market StabilizationOBV Trend Line - dars.gov.et
Kyverna Therapeutics to Participate in Upcoming September Invest - GuruFocus
Lupus Nephritis Clinical Trial Landscape Becomes Increasingly Crowded with 30+ Pharma Companies | DelveInsight - GlobeNewswire Inc.
Kyverna Therapeutics (KYTX) Rises 1.62% as Stock Tests Key ResistanceTick Index - dars.gov.et
Kyverna vs. Vertex: Clinical-Stage Risk vs. Cash-Flow Stability in Biotech InvestingNews and Statistics - IndexBox
Kyverna Therapeutics vs. Vertex Pharmaceuticals: Which Drug Developer Stock Is a Better Buy in 2026? - The Motley Fool
Kyverna Therapeutics, Inc. (KYTX) Presents at Jefferies Global Healthcare Conference 2026Slideshow - Seeking Alpha
H.C. Wainwright reiterates Kyverna stock rating on autoimmune data - Investing.com UK
H.C. Wainwright reiterates Kyverna stock rating on autoimmune data By Investing.com - Investing.com Nigeria
Advancing CAR T for Drug-Free Remission in Autoimmune Disease with Kyverna Therapeutics' Dr Naji Gehchan - Bioprocess Online
KYTX Reiterates by HC Wainwright & Co. -- Price Target Maintained at $25 - GuruFocus
Kyverna Therapeutics (KYTX) Jefferies Global Healthcare Conference 2026 Summary - Quartr
William Blair Maintains Kyverna Therapeutics(KYTX.US) With Buy Rating - Moomoo
KYTX: Miv-cel delivers durable, drug-free remission in SPS and gMG with strong safety and market potential - TradingView
2.64%
자본화:
|
볼륨(24시간):